Medical Cannabis Is Now Schedule III — What the April 2026 Federal Order Means for Operators

On April 28, 2026, the most significant federal cannabis policy shift in over 50 years took effect. The Department of Justice, acting through the DEA, moved state-licensed medical marijuana and FDA-approved cannabis drug products from Schedule I to Schedule III of the Controlled Substances Act.

This is not pending. This is not proposed. This is live. If you operate a state-licensed medical cannabis business, your federal legal status has already changed. The question is whether your compliance program has caught up.

What Actually Changed

1. Section 280E Relief — Live for Medical Operators

For decades, IRC Section 280E prevented cannabis businesses from deducting ordinary business expenses — rent, payroll, marketing, utilities — because the federal government classified their product alongside heroin. Schedule III removes that restriction for state-licensed medical operators.

This is not a marginal tax adjustment. For a typical medical dispensary generating $3-5M in annual revenue, 280E was increasing effective tax rates to 70-80%. Removing it can mean hundreds of thousands of dollars per year in recovered cash flow. If you have not yet consulted with a cannabis-experienced tax professional about amending prior returns and restructuring your current tax position, that should be your first call this week.

2. DEA Registration — Now Required, Now Available

Schedule III substances are regulated under the federal registration framework. That means medical cannabis operators can now — and in many cases must — register with the DEA as manufacturers, distributors, or dispensers of controlled substances.

The DEA has opened registration pathways specifically for state-licensed medical cannabis businesses. Applications can be submitted now, and operators may continue conducting business under their state license while federal registration is pending.

DEA registration brings federal oversight: facility security standards, record-keeping requirements, and periodic federal inspections that operate independently of your state compliance program. This is a new compliance layer — not a replacement for state requirements, but an additional set of federal requirements stacked on top.

3. Federal Recognition of Medical Use

Schedule I means "no currently accepted medical use." Schedule III means the federal government recognizes accepted medical use. This changes the legal posture of medical cannabis in ways that extend beyond taxes and registration:

• Research: Scientists can study cannabis with fewer federal barriers. Clinical trial access expands. The evidence base for medical use will grow.
• Banking: Financial institutions that cited Schedule I as a reason to deny services to medical operators lose that basis. More banks will open accounts. SAFE Banking implications remain in play.
• ADA protections: Medical cannabis patients may now qualify for protections under the Americans with Disabilities Act — a legal argument that was not available under Schedule I.
• Firearms: The ATF is already drafting updates to federal firearms forms that acknowledge the legal status of medical marijuana patients.

What Did NOT Change

Other things that did not change:

• Interstate commerce remains prohibited. No cannabis product — medical or adult-use — may cross state lines under federal law.
• This is not federal legalization. Cannabis remains a controlled substance. Schedule III substances are still federally regulated — they simply have accepted medical use and lower abuse potential than Schedules I and II.
• State law remains the primary operational framework. Your state license, state inspections, state compliance requirements — all still govern your day-to-day operations.

The Two-Tier System — Compliance Complexity Ahead

The April order created something unprecedented: a two-tier federal classification system for the same plant. Medical cannabis is Schedule III. Adult-use cannabis is Schedule I. Same plant, same THC molecule, different federal legal status depending on which license you hold.

For operators in states with both medical and adult-use markets — which is most of them — this creates a compliance split that has never existed before. If you hold both a medical and an adult-use license, you may be operating under conflicting federal classifications simultaneously. Inventory tracking, tax treatment, banking relationships, and federal oversight obligations may differ between the two sides of your business.

This is where consulting demand is spiking. Operators who try to self-navigate the two-tier system are making expensive mistakes.

What Medical Operators Must Do Now

Step 1: Engage a Cannabis Tax Professional

280E relief is retroactive in the sense that amended returns may recover overpaid taxes for prior periods — but only if your tax advisor understands how to navigate the transition. Standard CPAs will not know how to handle this. You need someone with cannabis tax experience.

Step 2: Begin DEA Registration

If you are a state-licensed medical cannabis operator, begin the DEA registration process now. The application pathway is open. Operating under pending registration is permitted. Delaying creates a compliance gap that the DEA will eventually close — and retroactive penalties are a real risk.

Step 3: Audit Your Compliance Program for Federal Requirements

DEA registration brings federal facility security standards, record-keeping requirements, and inspection obligations. Your state compliance program is not sufficient for federal compliance. You need to audit your facility, your security systems, your inventory tracking, and your record-keeping against DEA standards — not just state standards.

Step 4: Separate Medical and Adult-Use Operations

If you operate both medical and adult-use licenses, you need to structurally separate the two operations. Separate inventory. Separate METRC tracking. Separate financials. Separate compliance programs. The two-tier federal classification means treating them as the same business is a liability.

The Bottom Line

Medical cannabis is Schedule III. That is a fact, not a prediction. The operators who act on it now — filing amended returns, registering with the DEA, upgrading their compliance programs — will capture the financial and operational benefits first. The operators who wait for clearer guidance will spend more money catching up and risk penalties for non-compliance with federal requirements they did not know applied to them.

The April 2026 order is the most significant change in federal cannabis policy in our lifetimes. But it is only the medical half of the story. The adult-use hearing concludes July 15. The trajectory favors rescheduling — but nothing is guaranteed until the final rule lands and survives the inevitable D.C. Circuit challenges.